<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066092</url>
  </required_header>
  <id_info>
    <org_study_id>20020112</org_study_id>
    <nct_id>NCT00066092</nct_id>
    <nct_alias>NCT00060229</nct_alias>
  </id_info>
  <brief_title>Pegfilgrastim PBPC Mobilization Study</brief_title>
  <official_title>Randomized, Double-Blind Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Pegfilgrastim or Filgrastim for Autologous Transplantation in Subjects With Hodgkin's or Non-Hodgkin's Lymphoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, multi-center study to assess the safety and effectiveness
      of using a single subcutaneous (under the skin) injection of pegfilgrastim or daily
      subcutaneous injections of Filgrastim to mobilize stem cells for autologous transplantation
      in patients with Hodgkin's or non-Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a research study for Hodgkin's Disease and Non-Hodgkin's Lymphoma (NHL) patients who
      will receive high-dose chemotherapy with autologous peripheral blood stem cell (PBSC or PBPC)
      transplant. The chemotherapy doses are high enough to severely suppress the bone marrow
      (where blood cells are made) and cause very low blood counts. A collection of stem cells
      (very young blood cells) followed by reinfusion to restore blood counts will be done to
      stimulate recovery of your blood counts. This procedure is called leukapheresis. Giving
      growth factors to patients is a method to increase the number of PBPC that can be collected
      during leukapheresis. This process of giving growth factors to patients is called
      mobilization (moving cells from the bone marrow to the peripheral blood where they can be
      collected). The purpose of this study is to determine if pegfilgrastim, an investigational
      drug, can safely and effectively mobilize stem cells. Filgrastim (also known as NEUPOGENÂ® or
      G-CSF) is approved by the FDA for stem cell mobilization. Pegfilgrastim is a modified version
      of Filgrastim that is longer acting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD34+ collection during the collection phase</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to ANC and platelet engraftment post-transplant</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Lymphoma</condition>
  <condition>Hodgkin's Lymphoma</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Hematology</condition>
  <condition>Oncology</condition>
  <arm_group>
    <arm_group_label>Pegfilgrastim 6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegfilgrastim 6 mg given once for PBPC mobilization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegfilgrastim 12 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegfilgrastim 12 mg given once for PBPC mobilization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>filgrastim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Filgrastim given daily for PBPC mobilization</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegfilgrastim 12 mg</intervention_name>
    <description>Pegfilgrastim 12 mg given once for PBPC mobilization</description>
    <arm_group_label>Pegfilgrastim 12 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Filgrastim given daily for PBPC mobilization</description>
    <arm_group_label>filgrastim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegfilgrastim 6 mg</intervention_name>
    <description>Pegfilgrastim 6 mg given once for PBPC mobilization</description>
    <arm_group_label>Pegfilgrastim 6 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Hodgkin's or non-Hodgkin's lymphoma patients suitable for an autologous PBPC
             transplant - No previous bone marrow or PBPC transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2003</study_first_submitted>
  <study_first_submitted_qc>August 4, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2003</study_first_posted>
  <last_update_submitted>February 20, 2008</last_update_submitted>
  <last_update_submitted_qc>February 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>PBPC transplant</keyword>
  <keyword>Hodgkin's Disease</keyword>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>NHL</keyword>
  <keyword>mobilization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

